Clinical Trial Update: Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind study evaluating the safety and efficacy of intraprostatic PRX302 for lower urinary tract symptoms due to Benign Prostatic Hy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• PRX302

Snippet

Sponsor: Sophiris Bio Corp | Conditions: Benign Prostatic Hyperplasia | Phase 3 | Status: COMPLETED